|
|
|
| Clinical Observation of Peginterferon α-2a Combined with Adefovir Dipivioxil Antivirus Treatment in Chronic Hepatitis B Patients with Low ALT Level |
| The First People’s Hospital of Fuzhou City，Fuzhou 338000，China |
|
|
|
|
Abstract Objective： To investigate the effect of antivirus treatment in chronic hepatitis B（ CHB） patients with low ALT level. Method： 156 CHB patients with low ALT level were equally randomly divided into 4 groups： the HBeAg （+） treatment group（ group A）for 42 cases and the control group（ group B）for 40 cases； the HBeAg（-） treatment group（ group C）for 36 cases and the corresponding control group（ group D）for 38 cases. The patients in the HBeAg（+） or HBeAg（-） treatment group were respectively given peginterferon α-2a（180 μg） once a week，after 24 weeks，these patients were added with Adefovir dipivioxil（10 mg） once a day ，after 48 weeks，Peginterferon α-2a was stoped and Adefovir dipivioxil was given continually to the patients.Two control groups were respectively given Adefovir dipivioxil（10 mg， once a day）， the stopping standand of antiviral drugs was according to the guideline of prevention and treatment for CHB in 2005，China.Result： The HBV-DNA conversion rates ，HBeAg conversion rates and the relapsing rate after stop of antivirus drugs for 24 weeks in group A were all significantly different from the group B（P<0.05）； the HBVDNA conversion rates after treatment for 24，48 and 72 weeks were not different between group C and group D（P>0.05），however， the relapsing rate after stop of antivirus drugs for 24 weeks in group C was significantly different from the group D（P<0.05）. Conclusion：Peginterferon α-2a combined with Adefovir dipivioxil treatment may enhance therapeutic effect and lower relapsing rate in HBeAg（+） CHB patients with low ALT level， furthermore， it can decrease relapsing rate for HBeAg（-） CHB patients.
|
|
|
|
|
|
|
|
|
